TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02017327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoprost
Description: Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumigan 0.01%
Description: Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumigan 0.03% Unit Dose
Description: Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
Study: NCT00970853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOM Program home visiting
Description: Mixed professional home visiting program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
Study: NCT02031770

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium bicarbonate
Description: Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium bicarbonate
Description: Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: subjects will receive no treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: subjects will receive no treatment
Study: NCT01486849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357
Description: Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets BID for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole 50 MG
Study: NCT02662257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery.
Study: NCT03237104

Intervention type: OTHER
Intervention: Immediate PT
Description: Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
Study: NCT02742428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systematic ascites evacuation
Description: Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acute paracentesis.
Description: Evacuation of a large (\>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview.
Description: Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview.
Description: Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life.
Description: Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life.
Description: Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional status.
Description: Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional status.
Description: Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
Study: NCT00525993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib 90mg 14 days
Description: each patient in this group will receive 90mg once daily, for the 14 days treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib 60mg daily for 14 days
Description: Patients in this group will receive 60mg of the drug, daily
Study: NCT01236300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system
Study: NCT04534478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Patients will be randomized 1: 1 between the two arms of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Patients will be randomized 1: 1 between the two arms of the study
Study: NCT03761615

Intervention type: DEVICE
Intervention: Dexcom G6 CGM
Description: All women in the study will be given Dexcom G6 CGM and a study glucometer.
Study: NCT02642445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Sympathetic Denervation
Description: We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
Study: NCT02026895

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic blood sample
Study: NCT01428284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Probenecid
Description: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
Study: NCT02327637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Activity
Description: Ambulation 150 feet, two times per day
Study: NCT02821507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus and cyclophosphamide
Study: NCT03812640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl suture
Description: Corneal suture with Vicryl suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon suture
Description: Corneal suture with Nylon suture
Study: NCT03297736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D CAD/CAM autograft prosthesis
Description: Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control device
Description: Surgical ossicular reconstruction with the standard available middle ear prosthesis.
Study: NCT02477059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: La saline solution is administered by intravenous infusion.
Study: NCT02567149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Cidofovir
Study: NCT03570931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
Study: NCT00005832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R115777
Description: 300mg/dose BID, PO, Days 1-21, q 28days
Study: NCT04288154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS Device On
Description: The EMS Device will turned on during exercise as opposed to it being turned off for control group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EMS Device Off
Description: The EMS Device will turned off during exercise as opposed to it being turned off for control group.
Study: NCT02248727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: somofilcon A lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: somofilcon A lens
Study: NCT01708642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Adrenaline infusion 0.05 microgram / kg / minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraoperative isotonic saline infusion as placebo for adrenaline.
Study: NCT01701739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Multiple doses of aleglitazar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: Single dose of digoxin
Study: NCT02626897

Intervention type: DEVICE
Group type: OTHER
Intervention: GENEActiv Original Accelerometer
Description: Wrist-worn device measuring accelerations as a measure of daily activity.

Intervention type: DEVICE
Group type: OTHER
Intervention: GENEActiv Original Accelerometer
Description: Wrist-worn device measuring accelerations as a measure of daily activity.

Intervention type: DEVICE
Group type: OTHER
Intervention: ActiGraph GT3X Accelerometer
Description: Wrist-worn device measuring accelerations as a measure of daily activity.

Intervention type: DEVICE
Group type: OTHER
Intervention: ActiGraph GT3X Accelerometer
Description: Wrist-worn device measuring accelerations as a measure of daily activity.
Study: NCT03917823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
Study: NCT01392911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: High dose rifampicin
Study: NCT02679898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unloaded-Whole Body Vibration (WBVT)
Description: The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loaded-Whole Body Vibration (WBVT)
Description: The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
Study: NCT03257007

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
Study: NCT02184078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Study: NCT03179332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® insulin lispro
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp®
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid®
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Study: NCT00258674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medicare Claims Feedback
Description: Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
Study: NCT01577992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa test
Description: Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa test
Description: Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: determination of objective and subjective pain threshold
Description: Test without levodopa intake
Study: NCT01119378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual isotope technique
Description: Dual isotope technique using stable isotopes
Study: NCT03430102

Intervention type: DIAGNOSTIC_TEST
Intervention: Indicor
Description: Calculation of LVEDP via analysis of PPG waveform with Valsalva
Study: NCT00801177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 1~100 mg I.V.
Study: NCT00258674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicare Claims Feedback
Description: Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicare Claims Feedback
Description: Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Record Review
Description: Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Record Review
Description: Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Resource Nurse
Description: Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
Study: NCT03886051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft before Orthodontic treatment
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment only
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
Study: NCT01885611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Drug Therapy (Novartis Ⓡ)
Description: The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Drug Therapy (Novartis Ⓡ)
Description: The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: cold-processed VCO
Study: NCT03655808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cells (BBCs)
Description: Airway epithelial cells were collected in patients of the cell treatment group by a disposable 2-mm brush in order to obtain BBCs. The obtained tissue were washed and enzymatically digested to form a single-cell suspension, which was then cultured under R-Clone system, a patented technique of Regend Therapeutics, Ltd.. For patients in the cell treatment group, on the basis of B-ACT therapy, they were also received autologous BBCs transplantation. Cell suspension was diluted with normal saline. Fibrotic bronchoscopy was guided into the lobular or segmental airways and cells were instilled into lobes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic airway clearance treatment （B-ACT）
Description: The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bronchoscopic airway clearance treatment （B-ACT）
Description: The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).